...
首页> 外文期刊>Cureus. >Failed Treatment of Classic Kaposi’s Sarcoma with Topical Timolol: Case Report and Review of the Literature
【24h】

Failed Treatment of Classic Kaposi’s Sarcoma with Topical Timolol: Case Report and Review of the Literature

机译:用局部蒂莫尔的案例报告和文学审查,对经典Kaposi的肉瘤进行治疗失败

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Classic Kaposi’s sarcoma (CKS) is an angioproliferative cutaneous neoplasm which currently lacks a well-defined treatment regimen. Because the disease is often localized, topical therapies offer therapeutic potential without the morbidity of systemic or surgical treatment. Timolol, a topical β-adrenergic receptor antagonist, has shown promise in the treatment of CKS in individual cases. Here we report a patient with classic Kaposi’s sarcoma who failed treatment with 0.5% topical timolol three times daily for 12 weeks. Topical timolol use has been previously reported in eight patients with CKS who all responded to treatment with no adverse effects. Our divergent experience from the literature implies that while topical timolol may be an effective and safe treatment alternative to traditional therapies for patients with CKS, further prospective studies are needed.
机译:经典的Kaposi的肉瘤(CKS)是一种血管普鲁普利的皮肤肿瘤,目前缺乏明确的治疗方案。由于该疾病通常是局部化的,局部疗法提供治疗潜力,而不会出现系统性或手术治疗的发病率。蒂莫尔是一个局部β-肾上腺素能受体拮抗剂,已经显示出在个体病例中治疗CKS的许可。在这里,我们向患有经典Kaposi的肉瘤的患者每天服用0.5%的局部蒂洛尔治疗,每天进行12周,持续12周。局部蒂莫尔使用先前已在八名患者中报道,患有任何反应治疗的CKS没有不良反应。我们从文献中的发散经验表明,旨在为CKS患者的传统疗法是一种有效和安全的治疗方法,而需要进一步的前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号